How to Compare HCP Targeting Data Providers for Campaign Measurement
How to compare HCP targeting data providers for campaign measurement, with pros and cons by category: claims, lab, EHR, specialty pharmacy, networks, identity.
The short answer
To compare HCP targeting data providers for campaign measurement, first group them by source (claims, lab and diagnostic, EHR, specialty pharmacy, professional networks, identity), because the source decides what they can see and measure. Then score each on coverage of your target list, attribution, latency, activation reach, measurement design, and independence. No single category is best: pick the one whose data observes the outcome you need to move.
Requests for "the best HCP targeting data provider, with pros and cons" come up constantly, and any list of named winners would be out of date or wrong for your brand. What holds up is understanding the categories, since a provider's source shapes almost everything it can do. This article stays vendor-neutral and gives you a scorecard you can apply to any shortlist.
It is part of the series on diagnostic data in precision medicine launches, but it applies to any HCP campaign.
The main categories of HCP targeting data providers
| Category | What it observes | Pros | Cons |
|---|---|---|---|
| Claims and prescription data | Diagnoses, procedures, fills, attributed to HCPs | Broad coverage, standard for Rx measurement, long history | Lag; misses cash and some channels; weak on lab results |
| Lab and diagnostic data | Test orders, test types, sometimes aggregate results | Sees the testing gate; useful before launch | Coverage uneven across lab types; ordering vs. treating attribution |
| EHR data | Clinical detail in participating systems | Rich clinical context; results and staging in some cases | Limited to participating systems; can be hard to activate |
| Specialty pharmacy and hub data | Dispensing, enrollment, access events | Close to the real start; useful for specialty brands | Narrow by design; contract-dependent |
| Professional networks and endemic platforms | Verified HCP users and their engagement | Strong identity; first-party engagement | Measures their own platform best; walled-garden reporting |
| Identity and onboarding providers | Links NPIs to digital IDs | Makes lists addressable across DSPs | No clinical signal; match rate varies by partner |
Most real providers blend categories. A claims aggregator may resell lab data. An identity provider may offer "prescriber audiences" built from licensed claims. Ask which source each specific audience comes from, not what the company is known for. The comparison of sources for measurement in particular is in claims data vs. EHR data vs. lab data for campaign measurement.
What actually differentiates one provider from another
Pitches emphasize audience size and proprietary models. The differences that change your results are more mundane:
- Coverage of your list. How many of your target NPIs does the provider see with meaningful signal?
- Attribution. How a claim, test, or fill gets assigned to an HCP.
- Latency. Time from event to file to activated audience.
- Activation reach. Match rates into the DSPs and platforms you buy. See why HCP match rates differ across partners.
- Measurement design. Whether they support holdouts, matched controls, and pre-period checks, or only exposed-group attribution.
- Independence. Whether the same company sells the audience and grades it.
Measurement: what to ask before you trust a report
A provider that sells both targeting and measurement will usually report attributed prescriptions among exposed HCPs. That number is not incrementality. The question to ask is how the provider builds the comparison group and whether you can define the holdout yourself before launch. Attributed vs. incremental prescriptions covers the distinction, and the MRC standards are a reasonable reference point for how impressions and audiences should be counted, even where a healthcare provider is not accredited.
For a precision medicine brand, add one more question: can the provider measure testing behavior as an outcome, or only prescriptions? If testing is your bottleneck, a measurement partner that cannot see it will under-credit the work that matters most early on.
An evaluation scorecard
Weight each criterion for your brand, score 1 to 5, and multiply. The weights below are illustrative for a biomarker-gated oncology launch.
| Criterion | Illustrative weight | What a 5 looks like |
|---|---|---|
| Coverage of target list | 20% | Signal on most top-decile NPIs, documented gaps |
| Attribution method | 15% | Written rule, share of records with valid individual NPI |
| Latency | 10% | Median and tail stated for your data type |
| Activation match rate | 15% | Rates by DSP on your actual list, not a benchmark |
| Measurement design | 20% | Supports buyer-defined holdouts and pre-period balance |
| Independence | 10% | Separate measurement or third-party validation allowed |
| Privacy documentation | 10% | Current de-identification determination, clear use terms |
Price is deliberately missing. Score capability first, then compare total cost on a shortlist; how HCP data products are priced and hidden costs in HCP data contracts help with that step. The general partner scorecard in the pharma programmatic partner RFP scorecard is useful if you are running a wider RFP.
Common mistakes in provider comparisons
- Comparing audience sizes instead of coverage of your own list.
- Accepting match rate benchmarks instead of testing your list in your DSPs.
- Letting the targeting vendor design the only measurement.
- Buying overlapping sources without checking overlap. See audience overlap analysis.
- Choosing a provider for prescribing data when the bottleneck is testing.
Practical takeaway
Send your top 500 target NPIs to each shortlisted provider under NDA and ask for three numbers back: how many they see with signal, the match rate into your two main DSPs, and the latency for the data behind the audience. Those three numbers will separate the shortlist faster than any demo.
Frequently asked questions
Which type of HCP data is best for campaign measurement?
It depends on the outcome you need to measure. Claims and prescription data are the usual choice for prescribing outcomes, lab data for testing behavior, and EHR data for clinical detail in covered systems. For a biomarker-gated drug, you often need two sources: one for testing and one for prescribing.
What differentiates one HCP targeting provider from another?
Mostly source, coverage, attribution, latency, and how activation and measurement connect. Two providers with similar audiences can differ sharply in which HCPs they see and how quickly their data refreshes. Ask for those specifics rather than comparing audience sizes.
Should the same vendor provide targeting and measurement?
It is convenient and sometimes fine, but it creates a conflict of interest when the vendor grades its own audience. If you use one vendor for both, ask for a holdout design you control, or validate with an independent measurement source.
Sources
- Media Rating Council, Standards and Guidelines
- U.S. Department of Health and Human Services, Guidance Regarding Methods for De-identification of PHI
- CMS, NPPES NPI Registry
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.